Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals Plc (BDRX) entered into a warrant inducement transaction with an accredited holder of its Series M, N and O warrants. The holder is exercising all of its Existing Warrants to purchase 2,204,218 ADSs at a reduced exercise price of $1.05 per ADS, generating anticipated gross proceeds of about $2.3 million before fees and expenses. In return, the holder will receive new Series P (New) Warrants for up to 4,408,436 ADSs, exercisable immediately at $1.05 per ADS for five years, with standard anti-dilution adjustments but no price protection for future offerings. The ADSs from the Existing Warrants are covered by an effective Form F-1 registration statement, while Biodexa has agreed to file a resale registration statement for the ADSs underlying the New Warrants and may owe liquidated damages if resale registration or legend removals are delayed. Maxim Group LLC will receive a cash fee equal to 8.0% of the gross proceeds as warrant inducement agent and financial advisor.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement for the resale by selling shareholders of up to 127,754,750 ordinary shares, represented by 2,555,095 ADSs, issuable upon exercise of outstanding warrants, and reported unaudited interim results for the six months ended June 30, 2026. The company advanced its pipeline, including the registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis, an investigator-sponsored Phase 2 trial in non-muscle invasive bladder cancer, and in-licensed MTX240, a novel “molecular glue” for GIST. For 1H26, it recorded no revenue, a reduced net loss of £1.84 million and higher R&D investment of £2.92 million, while cash fell to £3.23 million with a net operating cash outflow of £4.61 million. Despite a July 2026 fundraise of $3.5 million and access to an undrawn $26.08 million equity line, management discloses a material uncertainty about going concern, expecting the need for additional financing during Q4 2026 and noting potential risks to continued Nasdaq listing if proposed minimum market value rules take effect.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 17,150 ordinary shares, represented by 343 American Depositary Shares, and concurrently reported unaudited results for the six months ended June 30, 2026.
For 1H26, Biodexa recorded a net loss of £1.84 million, an improvement from £3.81 million in 1H25, on R&D costs of £2.92 million (up 75%) and administrative costs of £1.74 million (down 27%). Finance income was £2.47 million, mainly from a gain on an equity‑settled derivative liability linked to a lower share price. Cash used in operating activities was £4.61 million, leaving £3.23 million of cash at June 30, 2026.
The company advanced its GI cancer pipeline, including a registrational Phase 3 eRapa trial in FAP with 92 of 168 subjects enrolled and in‑licensed MTX240 for GIST. On July 1, 2026 it raised $3.5 million gross via ADS and warrant financing, and has $26.08 million remaining under a $35 million Equity Line of Credit. Directors nonetheless highlight a material uncertainty about going concern, as additional financing is expected to be required during Q4 2026 amid challenging micro‑cap biotech markets and potential Nasdaq minimum market value pressures.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 94,300 ordinary shares, represented by 1,886 American Depositary Shares, and concurrently furnished interim results for the six months ended June 30, 2026.
The company reported no revenue, a loss from operations of £4.21 million and a net loss of £1.84 million, improved from a £3.81 million loss a year earlier, helped by £2.47 million of finance income largely from a gain on a derivative liability. R&D expenses rose to £2.92 million (vs. £1.67 million), mainly from the Phase 3 eRapa FAP trial and new MTX240 GIST program, while administrative costs fell to £1.74 million (vs. £2.38 million).
Cash used in operations was £4.61 million, with total cash decreasing to £3.23 million at June 30, 2026. A July 1, 2026 financing raised $3.5 million gross via ADSs and pre-funded warrants, and the company retains $26.08 million undrawn under a $35 million Equity Line of Credit. The board highlights a material uncertainty related to going concern, noting that additional financing is expected to be required during Q4 2026.
Biodexa Pharmaceuticals Plc (BDRX) filed a prospectus supplement covering the resale by selling shareholders of up to 170,150 ordinary shares represented by 3,403 ADSs, and furnished unaudited results for the six months ended June 30, 2026.
Revenue was £0, while R&D costs rose 75% to £2.92 million, reflecting higher spend on the Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis and initiation of MTX240 for GIST. Administrative costs fell 27% to £1.74 million, helped by foreign exchange gains and lower professional fees. The net loss narrowed to £1.84 million from £3.81 million, supported by £2.47 million of finance income driven by a gain on an equity‑settled derivative liability.
Cash and cash equivalents were £3.23 million at June 30, 2026, after £4.61 million of operating cash outflow. A July 1, 2026 financing raised $3.5 million gross, and $26.08 million remains available under a $35 million Equity Line of Credit. Even so, the company discloses a material uncertainty about going concern, with forecasts indicating a need for further financing during Q4 2026, and notes potential risk from Nasdaq’s proposed $5 million minimum market value requirement. Clinically, eRapa’s Phase 3 FAP trial has recruited 92 of 168 subjects and MTX240 was in‑licensed as a new molecular glue program for GIST.
Biodexa Pharmaceuticals plc (BDRX) filed a prospectus supplement covering the resale by existing holders of 10,950 ordinary shares represented by 219 American Depositary Shares (ADSs), and at the same time furnished unaudited interim results for the six months ended June 30, 2026.
The company is advancing its oncology portfolio: the registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis has enrolled 92 of 168 planned subjects across the US and Europe, with Canadian sites expected in late 2026, and a Phase 2 trial in non-muscle invasive bladder cancer is fully enrolled with support from a $3.0 million grant. Biodexa also in-licensed MTX240, a novel “molecular glue” for treatment‑resistant GIST, and continues an investigator‑initiated Phase 2a trial of tolimidone in Type 1 diabetes. Financially, revenue remained £Nil, R&D spending rose 75% to £2.92 million, administrative costs fell 27%, and the net loss narrowed to £1.84 million from £3.81 million, aided by a £2.47 million finance gain from a derivative liability revaluation. Cash decreased to £3.23 million, with operating cash outflow of £4.61 million, partly mitigated by $3.5 million gross proceeds from a July 1, 2026 equity financing and access to an undrawn $26.08 million equity line, yet management discloses a material uncertainty about going concern given the need for additional funding in Q4 2026.
Biodexa Pharmaceuticals Plc (BDRX) has filed a prospectus supplement covering the resale of up to 29,926,150 ordinary shares represented by 598,523 ADSs by an existing selling shareholder and simultaneously reports unaudited results for the six months ended June 30, 2026. The supplement primarily incorporates the attached Form 6-K, including the Chief Executive’s Review, 1H26 Financial Review and interim financial statements, into existing registration statements. In 1H26, Biodexa advanced its registrational Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis, reaching 92 subjects enrolled across US and European sites, in-licensed MTX240 for GIST from Otsuka, and continued an investigator-led Phase 2 NMIBC trial and a Phase 2a tolimidone study in Type 1 diabetes. Financially, R&D spending rose 75% to £2.92 million as the pipeline expanded, while the net loss narrowed to £1.84 million helped by a £2.47 million finance gain from a fall in the share-price-linked derivative liability. Cash and cash equivalents declined to £3.23 million at June 30, 2026, with an additional $3.5 million gross raised on July 1, 2026, and £157.60 million of accumulated deficit; management explicitly highlights a material uncertainty about going concern given expected need for further financing in Q4 2026 despite access to an undrawn $26.08 million capacity under a $35 million Equity Line of Credit.
Biodexa Pharmaceuticals PLC (BDRX) filed a prospectus supplement updating its F-1 registration covering up to 97,800 ADS underlying pre-funded warrants, 1,219,512 ADS underlying Series L warrants, and 30,487 ADS underlying placement agent warrants, all issuable on a continuous basis. The supplement incorporates unaudited results for the six months ended June 30, 2026. Biodexa reported no revenue, a net loss of £1.84 million (improved from £3.81 million a year earlier), and R&D spending of £2.92 million, up 75%, driven mainly by the Phase 3 Serenta trial of eRapa and the new MTX240 GIST program. Cash and cash equivalents were £3.23 million at June 30, 2026, and a financing completed July 1, 2026 raised $3.5 million gross. The company highlights a material uncertainty regarding going concern, with forecasts indicating further financing needed during Q4 2026 and continued reliance on capital markets and a $35 million Equity Line of Credit, of which $26.08 million remained undrawn.
Biodexa Pharmaceuticals Plc (BDRX) reported unaudited results for the six months ended June 30, 2026, highlighting expanded R&D activity and a narrowed loss. Revenue was £0, while the loss for the period improved to £1.84 million from £3.81 million in 1H25, helped by a £2.47 million finance income gain mainly from revaluation of an equity-settled derivative liability.
R&D spend rose 75% to £2.92 million, driven by the Phase 3 “Serenta” trial of eRapa in Familial Adenomatous Polyposis and initiation of the MTX240 GIST program, while administrative costs fell 27% to £1.74 million. Cash and cash equivalents declined to £3.23 million at June 30, 2026 from £8.53 million at year-end 2025, with operating cash outflow of £4.61 million. A July 1, 2026 financing raised $3.5 million gross, and $26.08 million remains undrawn under a $35 million Equity Line of Credit. The company discloses a material uncertainty about going concern, expecting to need additional financing in Q4 2026.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 26,166 American Depositary Shares (ADSs) of Biodexa Pharmaceuticals Plc, representing 9.99% of this ADS class. Each ADS represents four hundred ordinary shares.
Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the ADSs, and exercises voting and investment power over these securities. Mr. Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these shares. Voting and dispositive powers are reported as shared for all 26,166 ADSs and sole power is reported as zero.